What is it about?

Chemotherapy can damage nerves and cause persistent pain, tingling, numbness, or unusual sensitivity to touch and temperature, a condition known as chemotherapy-induced peripheral neuropathy. Current treatments often provide limited relief, and there are no established medications that reliably prevent it. In this study, we tested KLS-13019, a synthetic compound related to cannabidiol (CBD), in rats receiving the chemotherapy drugs paclitaxel or oxaliplatin. KLS-13019 reduced sensitivity to touch and cold after neuropathy had developed and, when given alongside paclitaxel, prevented the development of pain-like sensitivity. Repeated treatment produced long-lasting effects without the loss of effectiveness seen with morphine, and KLS-13019 did not produce morphine-like behavioral effects or observable sedation in our testing. These findings suggest that KLS-13019 could represent a new approach to both preventing and treating chemotherapy-induced nerve pain. Because these studies were performed in animals, further research is needed to determine whether the same effects occur in people.

Featured Image

Why is it important?

Chemotherapy-induced peripheral neuropathy is a common and potentially long-lasting side effect of cancer treatment. It can interfere with daily activities, reduce quality of life, and in severe cases may require chemotherapy doses to be reduced or treatment to be stopped. Despite its clinical importance, there are currently no established drug treatments that reliably prevent this condition, and available approaches for relieving symptoms are often only partially effective. What makes this study particularly notable is that KLS-13019 was effective in several different settings. It reduced established pain-like sensitivity after treatment with two different chemotherapy drugs, remained effective during repeated dosing, and did not produce the sedation or morphine-like behavioral effects observed with opioid treatment. Most importantly, when KLS-13019 was given at the same time as paclitaxel, the animals did not develop the persistent sensitivity normally produced by chemotherapy. These findings suggest that KLS-13019 may offer a different therapeutic strategy: rather than simply reducing symptoms after nerve damage has occurred, it may have the potential to prevent or interrupt the processes that lead to persistent chemotherapy-induced nerve pain. Further studies will be needed to determine whether these benefits translate to patients.

Perspectives

One of the most exciting aspects of this work for me was seeing how consistently KLS-13019 performed across several different experiments. We initially approached it as a potential treatment for chemotherapy-induced nerve pain, but the results suggested something more interesting: when treatment was started soon after chemotherapy, the benefits could persist long after the drug was no longer being given, and administering KLS-13019 alongside chemotherapy prevented the pain-like sensitivity from developing in our model. Those findings raised questions that have continued to shape my research, particularly around why the timing of treatment matters and how targeting GPR55 might alter the transition from an acute response to persistent neuropathic pain. I hope this work ultimately contributes not only to the development of KLS-13019, but also to a better understanding of how chemotherapy-induced neuropathy develops and how we might intervene before it becomes a chronic problem.

Michael Ippolito
Temple University

Read the Original

This page is a summary of: KLS-13019, a Novel Structural Analogue of Cannabidiol and GPR55 Receptor Antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy in Rats, Journal of Pharmacology and Experimental Therapeutics, November 2024, Elsevier,
DOI: 10.1124/jpet.124.002190.
You can read the full text:

Read

Contributors

The following have contributed to this page